Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB

PURPOSE OF REVIEW: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus responsible for the aggressive coronavirus disease (COVID-19) pandemic. Recently, investigators have stipulated that COVID-19 patients receiving angiotensin-converting-enzyme inhibitors (ACEI) may be subject...

Descripción completa

Detalles Bibliográficos
Autores principales: Rico-Mesa, Juan Simon, White, Averi, Anderson, Allen S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Hot Topic
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154066/
https://www.ncbi.nlm.nih.gov/pubmed/32291526
http://dx.doi.org/10.1007/s11886-020-01291-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154066/
https://www.ncbi.nlm.nih.gov/pubmed/32291526
http://dx.doi.org/10.1007/s11886-020-01291-4

Ejemplares similares